BLIS Technologies Ltd

Chart & Performance

D1W1MN

P/E

24.43

P/S

1.77

EPS

0.00

Div Yield, %

—

Shrs. gr., 5y

2.92%

Rev. gr., 5y

2.05%

Revenues

12m

+10.27%

Net income

838k

+29.72%

CFO

+70.05%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company markets two strains of probiotic bacteria, which include BLIS K12, a probiotic supplement to support ear, nose, and throat health of young children, as well as for improving immunity and bad breath; BLIS M18, an oral probiotic to support teeth, gums, and dental health; and BLIS Q24, a probiotic supplement to balance and restore the skin microbiome, restoring the health, clarity, and radiance. It has operations in New Zealand, Asia Pacific, Europe, the Middle East, Africa, and North America. The company was incorporated in 2000 and is based in Dunedin, New Zealand.

URL

https://blis.co.nz/

IPO date

Jul 30, 2001

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title NZD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title NZD in thousands, except ratios and share amounts	2025‑03	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT